Table 1.
Pre-transplant characteristics of patients with mucormycosis, fusariosis, and controls
| Variable N (%) | Mucormycosis (n =72) | Fusariosis (n =52) | Controls (n = 11856) | p-value |
|---|---|---|---|---|
| Age, yrs [median (range)] | 47 (3 – 68) | 32 (1 – 63) | 34 (<1 – 79) | <0.001 |
| Gender, male | 47 (65%) | 31 (60%) | 6924 (58%) | 0.491 |
| KPS at HCT | 0.048 | |||
| ≥ 90% | 40(56%) | 31 (60%) | 8049 (68%) | |
| < 90% | 30 (42%) | 20 (38%) | 3330 (28%) | |
| unknown | 2 ( 3%) | 1 ( 2%) | 477 ( 4%) | |
| Co-morbid illness at HCT | ||||
| Pulmonary | 11 (15%) | 5 (10%) | 1059 (9%) | 0.183 |
| Endocrine | 9 (13%) | 5 (10%) | 888 (7%) | 0.353 |
| Autoimmune | 1 ( 1%) | 4 ( 8%) | 266 (2%) | 0.060 |
| Disease | 0.233 | |||
| AML/ALL/MDS | 42 (58%) | 24 (46%) | 6216 (52%) | |
| NHL/HL | 8 (11%) | 7 (13%) | 1088 ( 9%) | |
| CML | 7 (10%) | 4 ( 8%) | 1511 (13%) | |
| CLL | 5 ( 7%) | 1 ( 2%) | 375 ( 3%) | |
| SAA | 4 ( 6%) | 5 (10%) | 926 ( 8%) | |
| Plasma cell disorders | 0 | 3 ( 6%) | 207 ( 2%) | |
| Other diseases | 6 ( 8%) | 8 (15%) | 1455 (12%) | |
| Leukemia Disease Stage | 0.004 | |||
| Early | 15 (38%) | 11 (42%) | 3500 (53%) | |
| Intermediate | 11 (28%) | 9 (35%) | 1800 (27%) | |
| Advanced | 10 (25%) | 6 (23%) | 1162 (18%) | |
| Missing | 4 (10%) | 0 | 121 ( 2%) | |
| Donor/Recipient Gender Match | 0.293 | |||
| Female/Male | 21 (29%) | 17 (33%) | 2805 (24%) | |
| Female/Female | 8 (11%) | 9 (17%) | 2147 (18%) | |
| Male/Female | 13 (18%) | 9 (17%) | 2424 (20%) | |
| Male/Male | 20 (28%) | 13 (25%) | 3610 (30%) | |
| UNK/Male | 6 ( 8%) | 1 ( 2%) | 511 ( 4%) | |
| UNK/Female | 4 ( 6%) | 3 ( 6%) | 359 ( 3%) | |
| Donor/Recipient CMV status | 0.571 | |||
| Positive/Positive | 29 (40%) | 16 (31%) | 4289 (36%) | |
| Positive/Negative | 4 ( 6%) | 5 (10%) | 1189 (10%) | |
| Negative/Positive | 12 (17%) | 14 (27%) | 2395 (20%) | |
| Negative/Negative | 18 (25%) | 9 (17%) | 2799 (24%) | |
| Missing | 9 (13%) | 8 (15%) | 1184 (10%) | |
| Donor/Recipient HLA match | 0.229 | |||
| HLA-identical siblings | 42 (58%) | 26 (50%) | 7608 (64%) | |
| Other related | 4 ( 6%) | 5 (10%) | 591 ( 5%) | |
| Well-matched unrelated | 12 (17%) | 4 ( 8%) | 1439 (12%) | |
| Partially matched unrelated | 3 ( 4%) | 6 (12%) | 708 ( 6%) | |
| Mismatched unrelated | 2 ( 3%) | 1 ( 2%) | 190 ( 2%) | |
| Umbilical cord blood | 9 (13%) | 10 (19%) | 1228 (10%) | |
| Stem cell source | 0.037 | |||
| Bone marrow | 23 (32%) | 19 (37%) | 5408 (46%) | |
| Peripheral blood | 40 (56%) | 23 (44%) | 5220 (44%) | |
| Umbilical cord blood | 9 (13%) | 10 (19%) | 1228 (10%) | |
| GvHD Prophylaxis | 0.300 | |||
| T-cell depletion | 6 ( 8%) | 2 ( 4%) | 475 ( 4%) | |
| Tacrolimus ± Other | 24 (33%) | 14 (27%) | 3032 (26%) | |
| Cyclosporine ± Other | 39 (54%) | 35 (67%) | 7887 (66%) | |
| Other | 3 ( 4%) | 1 ( 2%) | 462 ( 4%) | |
| Year of Transplant | 0.044 | |||
| 1995 – April 2002 | 28 (39%) | 32 (62%) | 5632 (48%) | |
| May 2002 – 2008 | 44 (61%) | 20 (38%) | 6224 (52%) | |